Use of chloroquine, azithromycin and ivermectin during the COVID-19 pandemic: An integrative review
DOI:
https://doi.org/10.33448/rsd-v12i13.44225Keywords:
Azithromycin; Chloroquine; Ivermectin; COVID-19; Adverse effects.Abstract
During the COVID-19 pandemic, the scientific community vehemently searched for medicines that could help treat the disease in question. Medications such as chloroquine, azithromycin and ivermectin were used as self-medication, before confirming their effectiveness against the virus and the disease. After just over two years since the start of the global COVID pandemic, the way we take care of our health still raises hypotheses among the population about the different correct ways of dealing with the disease, stating that different approaches would be effective or not? The objective gathered evidence on the pharmacokinetics, proposed mechanism of action in COVID-19, adverse effects, efficacy and safety of chloroquine/hydroxychloroquine, azithromycin and ivermectin for prophylaxis and treatment of COVID-19. The methodology used was an integrative review, which followed the recommendations of the adapted PRISMA guideline. The literature search was conducted in the PubMed, LILACS and MEDLINE databases. A critical analysis was carried out to determine the methodological rigor of the studies, based on the assessment of the level of scientific evidence. The results showed that the use of hydroxychloroquine, chloroquine, azithromycin or ivermectin, in mild or severe forms of COVID-19, both in treatment and prophylaxis, did not demonstrate any benefit in reducing mortality, hospitalizations or other unfavorable outcomes, without limiting transmission. virus nor preventing the installation of infection. Concluding that the use of these aforementioned medications as prophylactic and therapeutic measures for COVID-19 is contraindicated, due to the lack of consistent favorable evidence and the numerous reports of adverse outcomes in such treatments.
References
Axfors, C., Schmitt, A. M., Janiaud, P., van’t Hooft, J., Abd-Elsalam, S., Abdo, E. F., Abella, B. S., Akram, J., Amaravadi, R. K., Angus, D. C., Arabi, Y. M., Azhar, S., Baden, L. R., Baker, A. W., Belkhir, L., Benfield, T., Berrevoets, M. A. H., Chen, C. P., Chen, T. C., & Hemkens, L. G. (2021). Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-22446-z
Barbosa, A. N., Chebabo, A., Starling, C., Pérez, C., Cunha, C. A., de Luna, D., Nunes, E. P., Zambrano, G., Ferreira, J. C., Croda, J., Falavigna, M., Gomes-da-Silva, M. M., Thormann, M., Cimerman, S., Parahiba, S. M., Tanni, S., Bernardo, W. M., & Rodriguez-Morales, A. J. (2023). Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Em Annals of Clinical Microbiology and Antimicrobials 22(1). https://doi.org/10.1186/s12941-023-00623-w
Das, R., Behera, B., Mishra, B., & Naik, S. (2020). Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-Analysis. Em Indian Journal of Medical Microbiology. 38(3–4), 265–272. https://doi.org/10.4103/ijmm.IJMM_20_330
Dauner, D. G., & Dauner, K. N. (2021). Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. Journal of the American Pharmacists Association, 61(3), 293–298. https://doi.org/10.1016/j.japh.2021.01.007
Della Porta, A., Bornstein, K., Coye, A., Montrief, T., Long, B., & Parris, M. A. (2020). Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. Em American Journal of Emergency Medicine. 38(10), 2209–2217. https://doi.org/10.1016/j.ajem.2020.07.030
Ferreira, P. M. P., de Sousa, R. W. R., Dittz, D., E Sousa, J. M. de C., Torres-Leal, F. L., & Bezerra, D. P. (2023). Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. Brazilian Journal of Pharmaceutical Sciences, 59. https://doi.org/10.1590/s2175-97902023e21067
Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1). https://doi.org/10.1016/j.ijantimicag.2020.105949
Gumilang, R. A., Siswanto, Anggraeni, V. Y., Trisnawati, I., Budiono, E., & Hartopo, A. B. (2021). QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia. Journal of Arrhythmia, 37(5), 1184–1195. https://doi.org/10.1002/joa3.12623
Heidary, F., & Gharebaghi, R. (2020). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. Em Journal of Antibiotics (Vol. 73, Número 9, p. 593–602). Springer Nature. https://doi.org/10.1038/s41429-020-0336-z
Izcovich, A., Peiris, S., Ragusa, M., Tortosa, F., Rada, G., Aldighieri, S., & Reveiz, L. (2022). Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin’s suggested benefits are mainly based on potentially biased results. Journal of Clinical Epidemiology, 144, 43–55. https://doi.org/10.1016/j.jclinepi.2021.12.018
Kamel, A. M., Monem, M. S. A., Sharaf, N. A., Magdy, N., & Farid, S. F. (2022). Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. Em Reviews in Medical Virology. 32(1). https://doi.org/10.1002/rmv.2258
Kashour, Z., Riaz, M., Garbati, M. A., AlDosary, O., Tlayjeh, H., Gerberi, D., Hassan Murad, M., Rizwan Sohail, M., Kashour, T., & Tleyjeh, I. M. (2021). Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 76(4), 30–42. https://doi.org/10.1093/JAC/DKAA403
Marcolino, M. S., Meira, K. C., Guimarães, N. S., Motta, P. P., Chagas, V. S., Kelles, S. M. B., de Sá, L. C., Valacio, R. A., & Ziegelmann, P. K. (2022). Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infectious Diseases, 22(1). https://doi.org/10.1186/s12879-022-07589-8
Meo, S. A., Zaidi, S. Z. A., Shang, T., Zhang, J. Y., Al-Khlaiwi, T., Bukhari, I. A., Akram, J., & Klonoff, D. C. (2020). Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University - Science, 32(7), 3159–3166. https://doi.org/10.1016/j.jksus.2020.09.002
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Gentile, N., Collins, S., McCarthy, M. W., Jayaweera, D., Castro, M., Sulkowski, M., McTigue, K., Thicklin, F., Felker, G. M., Ginde, A. A., Bramante, C. T., Slandzicki, A. J., Gabriel, A., Shah, N. S., Lenert, L. A., & Hernandez, A. F. (2022). Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA, 328(16), 1595–1603. https://doi.org/10.1001/jama.2022.18590
Nicol, M. R., Joshi, A., Rizk, M. L., Sabato, P. E., Savic, R. M., Wesche, D., Zheng, J. H., & Cook, J. (2020). Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. Em Clinical Pharmacology and Therapeutics. 108(6), 1135–1149.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology, 134, 178–189. https://doi.org/10.1016/j.jclinepi.2021.03.001
Rezai, M. S., Ahangarkani, F., Hill, A., Ellis, L., Mirchandani, M., Davoudi, A., Eslami, G., Roozbeh, F., Babamahmoodi, F., Rouhani, N., Alikhani, A., Najafi, N., Ghasemian, R., Mehravaran, H., Hajialibeig, A., Navaeifar, M. R., Shahbaznejad, L., Rahimzadeh, G., Saeedi, M., & Valadan, R. (2022). Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.919708
Sekhavati, E., Jafari, F., SeyedAlinaghi, S. A., Jamalimoghadamsiahkali, S., Sadr, S., Tabarestani, M., Pirhayati, M., Zendehdel, A., Manafi, N., Hajiabdolbaghi, M., Ahmadinejad, Z., Kouchak, H. E., Jafari, S., Khalili, H., Salehi, M., Seifi, A., Golestan, F. S., & Ghiasvand, F. (2020). Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. International Journal of Antimicrobial Agents, 56(4). https://doi.org/10.1016/j.ijantimicag.2020.106143
Shirazi, F. M., Mirzaei, R., Nakhaee, S., Nejatian, A., Ghafari, S., & Mehrpour, O. (2022). Repurposing the drug, ivermectin, in COVID-19: toxicological points of view. Em European Journal of Medical Research. 27(1). https://doi.org/10.1186/s40001-022-00645-8
Tavares De Souza, M., Dias Da Silva, M., & De Carvalho, R. (2010). Revisão integrativa: o que é e como fazer Integrative review: what is it? How to do it? (Vol. 8, Número 1).
Tleyjeh, I. M., Kashour, Z., AlDosary, O., Riaz, M., Tlayjeh, H., Garbati, M. A., Tleyjeh, R., Al-Mallah, M. H., Sohail, M. R., Gerberi, D., Bin Abdulhak, A. A., Giudicessi, J. R., Ackerman, M. J., & Kashour, T. (2021). Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 5(1), 137–150. https://doi.org/10.1016/j.mayocpiqo.2020.10.005
Touret, F., & de Lamballerie, X. (2020). Of chloroquine and COVID-19. Em Antiviral Research (Vol. 177). https://doi.org/10.1016/j.antiviral.2020.104762
Ursi, E. S., & Gavão, C. M. (2006). Prevenção de lesões de pele no perioperatório: revisão integrativa da literatura. Revista Latino-Americana de Enfermagem, 14(1), 124–131. https://doi.org/10.1590/S0104-11692006000100017
Yao, X., Yan, X., Wang, X., Cai, T., Zhang, S., Cui, C., Wang, X., Hou, Z., Liu, Q., Li, H., Lin, J., Xiong, Z., & Liu, D. (2021). Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European Journal of Clinical Pharmacology, 77(4), 583–593. https://doi.org/10.1007/s00228-020-03032-6
Yuan, Y., Jiao, B., Qu, L., Yang, D., & Liu, R. (2023). The development of COVID-19 treatment. Em Frontiers in Immunology (Vol. 14). Frontiers Media S.A. https://doi.org/10.3389/fimmu.2023.1125246
Zaidi, A. K., & Dehgani-Mobaraki, P. (2022). The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. Em Journal of Antibiotics 75(2), 60–71. https://doi.org/10.1038/s41429-021-00491-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Felipe Reis; Jailton de Jesus Rocha Junior; Angélica Augusta Grigoli Dominato
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
